Pharmacodynamic Effects of Vorapaxar in Patients With and Without Diabetes Mellitus: Results of the OPTIMUS-5 Study.

Abstract

Vorapaxar reduces thrombotic cardiovascular events at the expense of increased bleeding. However, the differential pharmacodynamic (PD) effects of vorapaxar according to diabetes mellitus (DM) status are unknown. Moreover, although withdrawal of aspirin has emerged as a bleeding reduction strategy, the PD effects of stopping aspirin in patients treated with vorapaxar also are unknown. In this prospective PD investigation, vorapaxar was associated with reduced platelet-mediated thrombogenicity without affecting clot kinetics irrespective of DM status. However, platelet-mediated thrombogenicity increased after aspirin withdrawal, particularly among patients with DM. (Optimizing anti-Platelet Therapy In diabetes MellitUS-5 Study [OPTIMUS-5]; NCT02548650).

• Authors: Francesco Franchi, Fabiana Rollini, Victor Kairouz, Jose Rivas Rios, Andrea Rivas, Malhar Agarwal, Maryuri Briceno, Mustafa Wali, Ahmed Nawaz, Gabriel Silva, Zubair Shaikh, Naji Maaliki, Latonya Been, Jason Piraino, Andres M Pineda, Siva Suryadevara, Daniel Soffer, Martin M Zenni, Lisa K Jennings, Theodore A Bass, Dominick J Angiolillo
• Journal: JACC. Basic to translational science (JACC Basic Transl Sci) Vol. 4 Issue 7 Pg. 763-775 (Nov 2019) ISSN: 2452-302X [Electronic] United States
• PMID: 31998847 (Publication Type: Journal Article)
• Copyright: © 2019 The Authors.